Fine Foods & Pharmaceuticals Ntm

AGM Information • Apr 17, 2025

Role

Company

Name Surname Shareholders' Meeting of Fine Foods & Pharmaceuticals N.T.M. S.p.A.

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Financial Statements for 2024 and €0.14 dividend distribution per share, up 16.7% compared to 2023, approved

eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Treasury share buyback and disposal plan approved

maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Remuneration Policy approved

Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero

solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Verdellino (Bergamo, Italy), 17 April 2025 - The Shareholders' Meeting of Fine Foods & Pharmaceuticals N.T.M. S.p.A. - an Italian independent Contract Development & Manufacturing Organisation (CDMO) specialising in the contract development and manufacturing of products for the nutraceutical, pharmaceutical, and cosmetics industries, listed on Euronext STAR Milan (ticker: FF) met today in ordinary session and passed the following resolutions:

ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Financial Statements for 2024 and profit allocation

simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea The Financial Statements as of 31 December 2024 were approved along with the Board of Directors' Report on Operations at today's Shareholders' Meeting. The Meeting took note of the Board of Statutory Auditors and Auditing Company's Reports. The Consolidated Financial Statements as of 31 December 2024, including the Consolidated Sustainability Report prepared under Legislative Decree no. 125/2024, were presented. The Shareholders' Meeting allocated the 2024 net profit of €12,037,024 to the extraordinary reserve.

archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Dividend distribution and payment

offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Following the Board of Directors' proposal, and as reported on 13 March, the Shareholders' Meeting decided to distribute a dividend of €0.14 per share, gross of withholding taxes, for each ordinary share (net of treasury shares) outstanding at the record date.

Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma The total dividend is approximately €3.8 million. The dividend will be paid by withdrawing the relevant sum from the distributable portion of the merger surplus reserve.

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia Under the "Regulation of Markets organised and managed by Borsa Italiana S.p.A.", the dividend will be paid in a single instalment on 30 April 2025, ex-dividend of coupon no. 8 for ordinary shares (ISIN IT0005215329) and coupon no. 7 for multiple-voting shares (ISIN IT0005345522) on 28 April 2025 and record date on 29 April 2025.

con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil

id moluptatur. Report on Remuneration Policy and Compensation

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime The Shareholders' Meeting resolved:

eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit • to approve the first section of the Report on the remuneration policy and compensation drawn up by the Board of Directors under Articles 123-ter of Legislative Decree no. 58/1998 and 84-quater of CONSOB Regulation no. 11971/1999;

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

simus.

Name Surname Role Company • to express a favourable opinion on the second section of the Report on remuneration policy and compensation drawn up by the Board of Directors under Articles 123-ter of Legislative Decree no. 58/1998 and 84-quater of CONSOB Regulation no. 11971/1999.

Authorisation to buyback and dispose of treasury shares

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum The Shareholders' Meeting renewed the Board of Directors authorisation, under the explanatory report prepared by the Board of Directors, to buyback and dispose of treasury shares, subject to the revocation of the unexecuted part of a previous Shareholders' Meeting authorisation dated 29 May 2024. The buyback authorisation will last 18 months from the Shareholders' Meeting date, while the authorisation to dispose is granted without time limits.

facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a ***

dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.

ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam ***

estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, The summary voting record and the minutes of the meeting will be available to the public under applicable laws and regulations.

Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? ***

Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent Contract Development & Manufacturing Organisation (CDMO) specialising in the contract development and manufacturing of products for the nutraceutical, pharmaceutical and cosmetics industries. Founded in 1984, Fine Foods proved to be a reliable and capable strategic partner for customers in the reference sectors. The company's organisation can provide successful design process and solid, long-term partnerships. The continuous search for excellence is part of the company's business model and includes research and development, innovation, process reliability, product quality, ESG, and sustainable management of the Group's supply chain. Fine Foods is a benefit corporation which relies on certifications and ratings under international standards. These guarantee its sustainability commitment across the business. Fine Foods is a growing and future-oriented company.

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea ***

eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime For further information: Fine Foods & Pharmaceuticals N.T.M. S.p.A. Tel +39 035 4821382 Investor Relations: ir@finefoods.it Media Relations: media.relations@finefoods.it